{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:18:08Z","timestamp":1792671488047,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009242","name":"DGOS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009242","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ctro.2024.100833","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T03:17:43Z","timestamp":1722395863000},"page":"100833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["NANO-GBM trial of AGuIX nanoparticles with radiotherapy and temozolomide in the treatment of newly diagnosed Glioblastoma: Phase 1b outcomes and MRI-based biodistribution"],"prefix":"10.1016","volume":"48","author":[{"given":"J.","family":"Biau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Durando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Boux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Molnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Leyrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Guillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lavielle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Cremillieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Seddik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dufort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"De Beaumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Thivat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Le Duc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2024.100833_b0005","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(11)61346-9","article-title":"Primary brain tumours in adults","volume":"379","author":"Ricard","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ctro.2024.100833_b0010","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2024.100833_b0015","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA - J Am Med Assoc"},{"key":"10.1016\/j.ctro.2024.100833_b0020","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.radonc.2010.08.020","article-title":"Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide","volume":"97","author":"Minniti","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2024.100833_b0025","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s12885-023-10829-y","article-title":"Phase I\/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol)","volume":"23","author":"Thivat","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctro.2024.100833_b0030","doi-asserted-by":"crossref","first-page":"418","DOI":"10.7150\/thno.14018","article-title":"Gadolinium-based nanoparticles and radiation therapy for multiple brain melanoma metastases: proof of concept before phase I trial","volume":"6","author":"Kotb","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.ctro.2024.100833_b0035","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/nbm.3295","article-title":"Orotracheal administration of contrast agents: a new protocol for brain tumor targeting","volume":"28","author":"Bianchi","year":"2015","journal-title":"NMR Biomed"},{"key":"10.1016\/j.ctro.2024.100833_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep29678","article-title":"The high radiosensitizing efficiency of a trace of gadolinium-based nanoparticles in tumors","volume":"6","author":"Dufort","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctro.2024.100833_b0045","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/smll.201401284","article-title":"Nebulized gadolinium-based nanoparticles: a theranostic approach for lung tumor imaging and radiosensitization","volume":"11","author":"Dufort","year":"2015","journal-title":"Small"},{"key":"10.1016\/j.ctro.2024.100833_b0050","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.radonc.2021.04.021","article-title":"Theranostic AGuIX nanoparticles as radiosensitizer: a phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial)","volume":"160","author":"Verry","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2024.100833_b0055","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.0006-341X.2000.01177.x","article-title":"Sequential designs for phase I clinical trials with late-onset toxicities","volume":"56","author":"Cheung","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.ctro.2024.100833_b0060","first-page":"116","article-title":"Radiation guidelines for gliomas","volume":"26","author":"Antoni","year":"2022","journal-title":"Cancer Radiother J Soc Francaise Radiother Oncol"},{"key":"10.1016\/j.ctro.2024.100833_b0065","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay5279","article-title":"Targeting brain metastases with ultrasmall theranostic nanoparticles, a first-in-human trial from an MRI perspective","volume":"6","author":"Verry","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.ctro.2024.100833_b0070","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/jmri.28509","article-title":"T1 mapping from MPRAGE acquisitions: application to the measurement of the concentration of nanoparticles in tumors for theranostic use","volume":"58","author":"Lavielle","year":"2023","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.ctro.2024.100833_b0075","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/mrm.10640","article-title":"Comparison of longitudinal metabolite relaxation times in different regions of the human brain at 1.5 and 3 tesla","volume":"50","author":"Ethofer","year":"2003","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.ctro.2024.100833_b0080","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1109\/TSMC.1979.4310076","article-title":"A threshold selection method from gray-level histograms","volume":"9","author":"Otsu","year":"1996","journal-title":"IEEE Trans Syst Man Cybern"},{"key":"10.1016\/j.ctro.2024.100833_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/adhm.202100656","article-title":"Quantitative tissue pharmacokinetics and EPR effect of AGuIX nanoparticles: a multimodal imaging study in an orthotopic glioblastoma rat model and healthy macaque","volume":"10","author":"Tran","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.ctro.2024.100833_b0090","doi-asserted-by":"crossref","first-page":"20140134","DOI":"10.1259\/bjr.20140134","article-title":"The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy","volume":"87","author":"Sancey","year":"2014","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ctro.2024.100833_b0095","first-page":"20180365","article-title":"AGuIX\u00ae from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine","volume":"92","author":"Lux","year":"2019","journal-title":"Br J Radiol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630824001101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630824001101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T11:13:19Z","timestamp":1728126799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630824001101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":19,"alternative-id":["S2405630824001101"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100833","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NANO-GBM trial of AGuIX nanoparticles with radiotherapy and temozolomide in the treatment of newly diagnosed Glioblastoma: Phase 1b outcomes and MRI-based biodistribution","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100833","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100833"}}